製品番号: HY-N0863

Methyl protodioscin

(別名: NSC-698790; Smilax saponin B)

カスタマーレビュー

Based on 1 Customer Validation

Methyl protodioscin (NSC-698790; Smilax saponin B) is a multi-target, selective, steroidal diglycoside inhibitor with antitumor activity that induces cell cycle arrest. The mechanism of action of Methyl protodioscin is complex, involving the induction of G2/M cell cycle arrest, regulation of the Bcl-2/Bax apoptotic pathway, inhibition of the Akt1/c-Myc axis and MAPK/ERK signaling, while simultaneously downregulating ADAM15 and inducing FOXO1 to reduce cholesterol synthesis. It also inhibits the JNK/c-Jun pathway, reducing the production of inflammatory factors (IL-6, TNF-α). Methyl protodioscin exhibits significant antitumor (inhibiting proliferation, migration, invasion, and inducing apoptosis), anti-inflammatory, and anti-restenosis activities. Methyl protodioscin can be used in research on lung cancer, prostate cancer, pancreatic cancer, and other tumors, as well as inflammatory diseases such as airway inflammation and enteritis.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.67%
CAS 番号: 54522-52-0
分子式: C₅₂H₈₆O₂₂
分子量:1063.23

保管条件:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Methyl protodioscin 構造式

CAS 番号: 54522-52-0

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- Cellular Effect
- 体外実験
- 体内実験
化学情報
溶剤 & 溶解度
- 体外
- 体内
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

Bcl-2 Family アイソフォーム固有の製品をすべて表示 :

Akt アイソフォーム固有の製品をすべて表示 :

ERK アイソフォーム固有の製品をすべて表示 :

p38 MAPK アイソフォーム固有の製品をすべて表示 :

JNK アイソフォーム固有の製品をすべて表示 :

FOXO アイソフォーム固有の製品をすべて表示 :

FOXO1
FOXO3

Cellular Effect

Cell Line	Type	Value	Description	References
A7R5	IC₅₀	9 μM Compound: 1	Antiproliferative activity against rat A7r5 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against rat A7r5 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 27227546]
HL-60	IC₅₀	7.3 μM Compound: 10	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 12828464]

体外実験

Methyl protodioscin (10 nM-0.1 μM; 48 h) was screened in vitro against 60 human cancer cell lines, showing strong cytotoxicity against most solid tumor cells (GI₅₀ ≤ 10.0 μM), with the strongest selectivity against colon cancer cells HCT-15 (GI₅₀ = 1.93 μM) and breast cancer cells MDA-MB-435 (GI₅₀ = 1.69 μM), and moderate toxicity against leukemia cells (GI₅₀ 10-30 μM); the GI₅₀ values ??of methyl protodioscin against various tumor cells ranged from 1.69 to 50 μM (e.g., MDA-MB-435: 1.69 μM, DU145: approximately 4 μM), and the IC₅₀ against vascular smooth muscle cells A7r5 was approximately 9 μM^[1].
Methyl protodioscin (5-20 μM; 48 h) dose-dependently inhibited proliferation in A549 lung cancer cells, inducing G2/M phase cell cycle arrest and apoptosis, downregulating Bcl-2 expression, upregulating Bax expression, activating caspase-3, reducing mitochondrial membrane potential, and promoting cytochrome c release^[2].
Methyl protodioscin (1-10 μM; 24-48 h) inhibited proliferation (48-hour IC₅₀ approximately 4 μM), migration, and invasion in DU145 prostate cancer cells, inducing G2/M phase arrest and apoptosis, downregulating SREBP1, SREBP2, and HMGCR mRNA expression, upregulating ABCA1 and FOXO1 protein expression, and inhibiting P-ERK activity^[3].
Methyl protodioscin (15-50 μM; 24-48 h) in PANC-1 (IC₅₀ = 34.4 μM) and MIA PaCa-2 (IC₅₀ = 50 μM) In pancreatic cancer cells, methyl protodioscin inhibits proliferation, induces G2/M phase arrest and apoptosis, downregulates the expression of glycolysis-related genes Glut1, HK2, LDHA, and PDK1, and inhibits the Akt1/c-Myc signaling pathway^[4].
Methyl protodioscin (1-100 ng/mL; 12-48 h) repairs inflammation-induced barrier function damage in Caco-2 intestinal epithelial cells, promotes crypt formation in mouse intestinal crypt cultures (10 ng/mL being optimal), and upregulates RegIIIc mRNA expression^[5].
Methyl protodioscin (3-9 μM; 16-24 h) inhibits proliferation (IC₅₀ approximately 9 μM) and migration in A7r5 vascular smooth muscle cells, induces G0/G1 phase arrest, and downregulates the protein expression and activity of ADAM15, P-FAK, P-ERK, and MMP-2/9^[6].
Methyl protodioscin (10-100 μM; 4 h) inhibits IL-1β-induced IL-6, IL-8, and TNF-α production in A549 cells and inhibits JNK/c-Jun activation; 100 μM treatment of MH-S macrophages for 24 hours slightly inhibits NO production, but this is accompanied by slight cytotoxicity^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

体内実験

Methyl protodioscin (0.5 mg/kg, 1 mg/kg; tail vein injection; once daily; 15 days) significantly reduced tumor volume and weight, decreased cholesterol concentration in tumor tissue, induced FOXO1 expression, inhibited P-ERK activity, upregulated Bax, cleaved caspase-3, and cleaved PARP expression, downregulated Bcl-2 expression, and promoted tumor cell apoptosis in a subcutaneous prostate cancer RM-1 cell xenograft model in male C57BL/6 mice^[3].
Methyl protodioscin (100 mg/kg; intravenous injection; frequency and duration not specified) inhibited tumor growth, reduced ¹⁸F-FDG uptake in tumor tissue, and inhibited glycolysis in vivo in a subcutaneous pancreatic cancer MIA PaCa-2 cell xenograft model in BALB/c-nu mice^[4].
Methyl protodioscin (25 mg/kg; intraperitoneal injection; once daily; 5 days/10 days) increased the survival rate of 4% DSS-induced mice, promoted mucosal healing in 2.5% DSS-induced mice, reduced colon inflammation scores, decreased NF-κB activation and inflammatory cytokine (TNF-α, IL-17, IL-23) production, and reduced bacterial translocation to mesenteric lymph nodes in a DSS (HY-116282C)-induced colitis model in C57BL/6 mice^[5].
Methyl protodioscin (25 mg/kg; intraperitoneal injection; once daily; 7 days) alleviated colon inflammation, reduced bacterial colonization and translocation to mesenteric lymph nodes, and restored body weight and colon length in a Citrobacter rodentium infection-induced colitis model in C57BL/6 mice^[5].
Methyl protodioscin (3 μM, 6 μM; topical application; single administration; 2 weeks) significantly reduced neointimal formation, decreased the neointima/media area ratio, and downregulated ADAM15 in vascular tissue in a carotid artery balloon injury model in male rats^[6].
Protein expression^[6].
Methyl protodioscin (30 mg/kg, 60 mg/kg; oral administration; single dose; 16 h) reduced total cell and neutrophil/macrophage infiltration in bronchoalveolar lavage fluid, decreased mRNA expression of IL-6, IL-1β, and TNF-α in lung tissue, and improved pathological changes such as alveolar wall thickening and alveolar lumen narrowing in a LPS-induced acute lung injury model in male ICR mice^[7].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

化学情報

CAS 番号 54522-52-0
性状 Solid
分子量 1063.23
分子式 C₅₂H₈₆O₂₂
Color White to off-white
SMILES

C[C@@]1([C@]([C@@H]2C)([H])[C@](O[C@]2(OC)CC[C@@H](C)CO[C@@H]([C@@H]([C@@H](O)[C@@H]3O)O)O[C@@H]3CO)([H])C4)[C@]4([H])[C@@](CC=C5[C@@]6(CC[C@H](O[C@@](O[C@H](CO)[C@@H](O[C@@](O[C@@H](C)[C@H](O)[C@H]7O)([H])[C@@H]7O)[C@@H]8O)([H])[C@@H]8O[C@@](O[C@@H](C)[C@H](O)[C@H]9O)([H])[C@@H]9O)C5)C)([H])[C@]6([H])CC1
別名

NSC-698790; Smilax saponin B
Structure Classification
- Steroids
Initial Source
- Plants
- other families
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶剤 & 溶解度

体外:

DMSO : 100 mg/mL (94.05 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

0.9405 mL

4.7027 mL

9.4053 mL

5 mM

0.1881 mL

0.9405 mL

1.8811 mL

10 mM

0.0941 mL

0.4703 mL

0.9405 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 3.5 mg/mL (3.29 mM); Clear solution

This protocol yields a clear solution of ≥ 3.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (35.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 3.5 mg/mL (3.29 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 3.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (35.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 3.5 mg/mL (3.29 mM); Clear solution

This protocol yields a clear solution of ≥ 3.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (35.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (283 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Hu K, et al. The cytotoxicity of methyl protodioscin against human cancer cell lines in vitro. Cancer Invest. 2003 Jun;21(3):389-93. [Content Brief]

[2]. Bai Y, et al. Methyl protodioscin induces G2/M cell cycle arrest and apoptosis in A549 human lung cancer cells. Pharmacogn Mag. 2014 Jul;10(39):318-24. [Content Brief]

[3]. Chen J, et al. Anticancer Activity of Methyl Protodioscin against Prostate Cancer by Modulation of Cholesterol-Associated MAPK Signaling Pathway via FOXO1 Induction. Biol Pharm Bull. 2023;46(4):574-585. [Content Brief]

[4]. Chen L, et al. Natural Compound Methyl Protodioscin Suppresses Proliferation and Inhibits Glycolysis in Pancreatic Cancer. Evid Based Complement Alternat Med. 2018 Mar 15;2018:7343090. [Content Brief]

[5]. Zhang R, et al. Natural compound methyl protodioscin protects against intestinal inflammation through modulation of intestinal immune responses. Pharmacol Res Perspect. 2015 Mar;3(2):e00118. [Content Brief]

[6]. Chung YL, et al. Methyl Protodioscin, a Steroidal Saponin, Inhibits Neointima Formation in Vitro and in Vivo. J Nat Prod. 2016 Jun 24;79(6):1635-44. [Content Brief]

[7]. Lee JH, et al. Methyl Protodioscin from the Roots of Asparagus cochinchinensis Attenuates Airway Inflammation by Inhibiting Cytokine Production. Evid Based Complement Alternat Med. 2015;2015:640846. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	0.9405 mL	4.7027 mL	9.4053 mL	23.5133 mL
	5 mM	0.1881 mL	0.9405 mL	1.8811 mL	4.7027 mL
	10 mM	0.0941 mL	0.4703 mL	0.9405 mL	2.3513 mL
	15 mM	0.0627 mL	0.3135 mL	0.6270 mL	1.5676 mL
	20 mM	0.0470 mL	0.2351 mL	0.4703 mL	1.1757 mL
	25 mM	0.0376 mL	0.1881 mL	0.3762 mL	0.9405 mL
	30 mM	0.0314 mL	0.1568 mL	0.3135 mL	0.7838 mL
	40 mM	0.0235 mL	0.1176 mL	0.2351 mL	0.5878 mL
	50 mM	0.0188 mL	0.0941 mL	0.1881 mL	0.4703 mL
	60 mM	0.0157 mL	0.0784 mL	0.1568 mL	0.3919 mL
	80 mM	0.0118 mL	0.0588 mL	0.1176 mL	0.2939 mL

Keywords

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Methyl protodioscin

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

MAPK Compound Library

Metabolism/Protease Compound Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Glycoside Compound Library

Lipid Compound Library

Oxygen Sensing Compound Library

Medicine Food Homology Compound Library

Glycolysis Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Mitochondria-Targeted Compound Library

Transcription Factor-Targeted Library

Glucose Metabolism Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Mitophagy Compound Library

Bioactive Compound Library Max

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

Lactic Acid Metabolic Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Anti-Rheumatic Arthritis Compound Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Bcl-2 Family アイソフォーム固有の製品をすべて表示

Akt アイソフォーム固有の製品をすべて表示

ERK アイソフォーム固有の製品をすべて表示